Modeling the Kinetics of Digoxin Absorption: Enhancement by P-Glycoprotein Inhibition

被引:12
|
作者
Weiss, Michael [1 ,2 ]
Sermsappasuk, Pakawadee [2 ]
Siegmund, Werner [3 ]
机构
[1] Univ Halle Wittenberg, Dept Pharmacol, D-06097 Halle, Saale, Germany
[2] Naresuan Univ, Fac Pharmaceut Sci, Phitsanulok, Thailand
[3] Ernst Moritz Arndt Univ Greifswald, Inst Pharmacol, Div Clin Pharmacol, Greifswald, Germany
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2012年 / 52卷 / 03期
关键词
P-glycoprotein inhibition; digoxin; bioavailability; absorption rate; population pharmacokinetics; ORAL BIOAVAILABILITY; PHARMACOKINETICS;
D O I
10.1177/0091270010396711
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An increase in the area under the curve (AUC) after oral digoxin due to coadministration of drugs known as P-glycoprotein (P-gp) inhibitors has been reported in several studies, but there is very little information on the rate of absorption after P-gp inhibition. Based on an inverse Gaussian density absorption model and using a population approach, the authors reanalyzed data showing an increase in oral digoxin AUC in healthy volunteers after coadministration of talinolol. The model fitted the data well, and the results revealed that the maximum rate of digoxin absorption increased nearly 2-fold, whereas bioavailability increased only by 21%. It is concluded that the increase in the rate of absorption seems to be a better indicator of intestinal P-gp inhibition than the increase in extent of absorption. Furthermore, the authors use a simulation study to demonstrate the ability of the method to estimate bioavailability based on the population characteristics of digoxin disposition kinetics obtained from a different group of healthy volunteers.
引用
收藏
页码:381 / 387
页数:7
相关论文
共 50 条
  • [1] Evidence for Enhanced Intestinal Absorption of Digoxin by P-Glycoprotein Inhibitors
    Valizadeh, Hadi
    Mehtari, Maryam
    Zakeri-Milani, Parvin
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2012, 11 (06) : 939 - 945
  • [2] Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition
    Verstuyft, C
    Strabach, S
    El Morabet, H
    Kerb, R
    Brinkmann, U
    Dubert, L
    Jaillon, P
    Funck-Brentano, C
    Trugnan, G
    Becquemont, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) : 51 - 60
  • [3] The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats
    Sababi, M
    Borgå, O
    Hultkvist-Bengtsson, U
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (01) : 21 - 27
  • [4] THE EFFECTS OF P-GLYCOPROTEIN INHIBITION ON DIGOXIN PHARMACODYNAMICS IN ISOLATED RAT HEARTS
    Arici, A.
    Kilinc, E.
    Demir, O.
    Ates, M.
    Gelal, A.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 73 - 73
  • [5] Gastrointestinal absorption of pimozide is enhanced by inhibition of P-glycoprotein
    Morishita, Hiroki
    Okawa, Kozue
    Ishii, Misaki
    Mizoi, Kenta
    Ito, Masa-aki
    Arakawa, Hiroshi
    Yano, Kentaro
    Ogihara, Takuo
    PLOS ONE, 2020, 15 (10):
  • [6] INHIBITION OF INTESTINAL P-GLYCOPROTEIN AND EFFECTS ON ETOPOSIDE ABSORPTION
    LEU, BL
    HUANG, JD
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (05) : 432 - 436
  • [7] Calorie Restriction Increases P-Glycoprotein and Decreases Intestinal Absorption of Digoxin in Mice
    Renaud, Helen J.
    Klaassen, Curtis D.
    Csanaky, Ivan L.
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (03) : 366 - 369
  • [8] Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability
    Varma, MVS
    Panchagnula, R
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (08) : 1694 - 1704
  • [9] Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin
    Chiney, Manoj S.
    Menon, Rajeev M.
    Bueno, Orlando F.
    Tong, Bo
    Salem, Ahmed Hamed
    XENOBIOTICA, 2018, 48 (09) : 904 - 910